249 related articles for article (PubMed ID: 34762234)
1. Targeting the cytochrome bc
Wani MA; Dhaked DK
Mol Divers; 2022 Oct; 26(5):2949-2965. PubMed ID: 34762234
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome bc1-aa3 Oxidase Supercomplex As Emerging and Potential Drug Target Against Tuberculosis.
Sindhu T; Debnath P
Curr Mol Pharmacol; 2022; 15(2):380-392. PubMed ID: 34602044
[TBL] [Abstract][Full Text] [Related]
3. Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis.
Foo CS; Lupien A; Kienle M; Vocat A; Benjak A; Sommer R; Lamprecht DA; Steyn AJC; Pethe K; Piton J; Altmann KH; Cole ST
mBio; 2018 Oct; 9(5):. PubMed ID: 30301850
[TBL] [Abstract][Full Text] [Related]
4. Investigation of protein-ligand binding motions through protein conformational morphing and clustering of cytochrome bc1-aa3 super complex.
Sindhu T; Rajamanikandan S; Jeyakanthan J; Pal D
J Mol Graph Model; 2023 Jan; 118():108347. PubMed ID: 36208591
[TBL] [Abstract][Full Text] [Related]
5. Exploiting the synthetic lethality between terminal respiratory oxidases to kill
Kalia NP; Hasenoehrl EJ; Ab Rahman NB; Koh VH; Ang MLT; Sajorda DR; Hards K; Grüber G; Alonso S; Cook GM; Berney M; Pethe K
Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7426-7431. PubMed ID: 28652330
[TBL] [Abstract][Full Text] [Related]
6. Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?
Bajeli S; Baid N; Kaur M; Pawar GP; Chaudhari VD; Kumar A
Front Cell Infect Microbiol; 2020; 10():589318. PubMed ID: 33330134
[TBL] [Abstract][Full Text] [Related]
7. Cryo-Electron Microscopy Structure of the
Mathiyazakan V; Wong CF; Harikishore A; Pethe K; Grüber G
Antimicrob Agents Chemother; 2023 Jun; 67(6):e0153122. PubMed ID: 37158740
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of (Quinazoline 4-yloxy)acetamide and (4-oxoquinazoline-3(4H)-yl)acetamide derivatives as inhibitors of Mycobacterium tuberculosis bd oxidase.
Kumar A; Kumari N; Bhattacherjee S; Venugopal U; Parwez S; Siddiqi MI; Krishnan MY; Panda G
Eur J Med Chem; 2022 Nov; 242():114639. PubMed ID: 35973312
[TBL] [Abstract][Full Text] [Related]
9. Carbon metabolism modulates the efficacy of drugs targeting the cytochrome bc
Kalia NP; Shi Lee B; Ab Rahman NB; Moraski GC; Miller MJ; Pethe K
Sci Rep; 2019 Jun; 9(1):8608. PubMed ID: 31197236
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Two Novel Inhibitors of the Mycobacterium tuberculosis Cytochrome
Gries R; Dal Molin M; Chhen J; van Gumpel E; Dreyer V; Niemann S; Rybniker J
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0025123. PubMed ID: 37358461
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antitubercular activity of novel 4-arylalkyl substituted thio-, oxy- and sulfoxy-quinoline analogues targeting the cytochrome bc1 complex.
Murnane R; Zloh M; Tanna S; Allen R; Santana-Gomez F; Parish T; Brucoli F
Bioorg Chem; 2023 Sep; 138():106659. PubMed ID: 37336104
[TBL] [Abstract][Full Text] [Related]
12. Isolation and Characterization of a Hybrid Respiratory Supercomplex Consisting of Mycobacterium tuberculosis Cytochrome bcc and Mycobacterium smegmatis Cytochrome aa3.
Kim MS; Jang J; Ab Rahman NB; Pethe K; Berry EA; Huang LS
J Biol Chem; 2015 Jun; 290(23):14350-60. PubMed ID: 25861988
[TBL] [Abstract][Full Text] [Related]
13. Targeting the cytochrome oxidases for drug development in mycobacteria.
Lee BS; Sviriaeva E; Pethe K
Prog Biophys Mol Biol; 2020 May; 152():45-54. PubMed ID: 32081616
[TBL] [Abstract][Full Text] [Related]
14. Identification of 4-Amino-Thieno[2,3-
Harrison GA; Mayer Bridwell AE; Singh M; Jayaraman K; Weiss LA; Kinsella RL; Aneke JS; Flentie K; Schene ME; Gaggioli M; Solomon SD; Wildman SA; Meyers MJ; Stallings CL
mSphere; 2019 Sep; 4(5):. PubMed ID: 31511370
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.
Lee BS; Hards K; Engelhart CA; Hasenoehrl EJ; Kalia NP; Mackenzie JS; Sviriaeva E; Chong SMS; Manimekalai MSS; Koh VH; Chan J; Xu J; Alonso S; Miller MJ; Steyn AJC; Grüber G; Schnappinger D; Berney M; Cook GM; Moraski GC; Pethe K
EMBO Mol Med; 2021 Jan; 13(1):e13207. PubMed ID: 33283973
[TBL] [Abstract][Full Text] [Related]
16. Naturally-Occurring Polymorphisms in QcrB Are Responsible for Resistance to Telacebec in
Sorayah R; Manimekalai MSS; Shin SJ; Koh WJ; Grüber G; Pethe K
ACS Infect Dis; 2019 Dec; 5(12):2055-2060. PubMed ID: 31599569
[No Abstract] [Full Text] [Related]
17. QcrB in Mycobacterium tuberculosis: The new drug target of antitubercular agents.
Bahuguna A; Rawat S; Rawat DS
Med Res Rev; 2021 Jul; 41(4):2565-2581. PubMed ID: 33400275
[TBL] [Abstract][Full Text] [Related]
18. Nitric Oxide-Dependent Electron Transport Chain Inhibition by the Cytochrome
Zeng S; Zhang J; Sun M; Zhang X; Cook GM; Zhang T
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0095621. PubMed ID: 34152815
[TBL] [Abstract][Full Text] [Related]
19. Identification of Surf1 as an assembly factor of the cytochrome bc
Davoudi CF; Ramp P; Baumgart M; Bott M
Biochim Biophys Acta Bioenerg; 2019 Oct; 1860(10):148033. PubMed ID: 31226315
[TBL] [Abstract][Full Text] [Related]
20. Response of
Chauhan P; van der Meulen SA; Simões Caetano JM; Goojani HG; Botman D; van Spanning R; Lill H; Bald D
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
